Cryo-Cell International is engaged in cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacture of PrepaCyte® CB Processing System units, the processing technology used to process umbilical cord blood stem cells and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Co. stores cord blood and cord tissue specimens for the benefit of newborn babies and possibly other members of their families. Co. also provides cord tissue service, which stores a section of the umbilical cord tissue. The CCEL stock yearly return is shown above.
The yearly return on the CCEL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CCEL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|